These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 39054363)

  • 1. Tofersen decreases neurofilament levels supporting the pathogenesis of the SOD1 p.D91A variant in amyotrophic lateral sclerosis patients.
    Weishaupt JH; Körtvélyessy P; Schumann P; Valkadinov I; Weyen U; Hesebeck-Brinckmann J; Weishaupt K; Endres M; Andersen PM; Regensburger M; Dreger M; Koch JC; Conrad J; Meyer T
    Commun Med (Lond); 2024 Jul; 4(1):150. PubMed ID: 39054363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and patient-reported outcomes and neurofilament response during tofersen treatment in SOD1-related ALS-A multicenter observational study over 18 months.
    Meyer T; Schumann P; Weydt P; Petri S; Weishaupt JH; Weyen U; Koch JC; Günther R; Regensburger M; Boentert M; Wiesenfarth M; Koc Y; Kolzarek F; Kettemann D; Norden J; Bernsen S; Elmas Z; Conrad J; Valkadinov I; Vidovic M; Dorst J; Ludolph AC; Hesebeck-Brinckmann J; Spittel S; Münch C; Maier A; Körtvélyessy P
    Muscle Nerve; 2024 Sep; 70(3):333-345. PubMed ID: 39031772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS: Treatment experience in clinical practice.
    Meyer T; Schumann P; Weydt P; Petri S; Koc Y; Spittel S; Bernsen S; Günther R; Weishaupt JH; Dreger M; Kolzarek F; Kettemann D; Norden J; Boentert M; Vidovic M; Meisel C; Münch C; Maier A; Körtvélyessy P
    Muscle Nerve; 2023 Jun; 67(6):515-521. PubMed ID: 36928619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characterization of common pathogenic variants of SOD1-ALS in Germany.
    Wiesenfarth M; Forouhideh-Wiesenfarth Y; Elmas Z; Parlak Ö; Weiland U; Herrmann C; Schuster J; Freischmidt A; Müller K; Siebert R; Günther K; Fröhlich E; Knehr A; Simak T; Bachhuber F; Regensburger M; Petri S; Klopstock T; Reilich P; Schöberl F; Schumann P; Körtvélyessy P; Meyer T; Ruf WP; Witzel S; Tumani H; Brenner D; Dorst J; Ludolph AC
    J Neurol; 2024 Oct; 271(10):6667-6679. PubMed ID: 39141064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tofersen for SOD1 ALS.
    Everett WH; Bucelli RC
    Neurodegener Dis Manag; 2024; 14(5):149-160. PubMed ID: 39330700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trial of Antisense Oligonucleotide Tofersen for
    Miller TM; Cudkowicz ME; Genge A; Shaw PJ; Sobue G; Bucelli RC; Chiò A; Van Damme P; Ludolph AC; Glass JD; Andrews JA; Babu S; Benatar M; McDermott CJ; Cochrane T; Chary S; Chew S; Zhu H; Wu F; Nestorov I; Graham D; Sun P; McNeill M; Fanning L; Ferguson TA; Fradette S;
    N Engl J Med; 2022 Sep; 387(12):1099-1110. PubMed ID: 36129998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SOD1 D91A variant in the southernmost tip of Europe: a heterozygous ALS patient resident on the island of Gozo.
    Farrugia Wismayer M; Farrugia Wismayer A; Pace A; Vassallo N; Cauchi RJ
    Eur J Hum Genet; 2022 Jul; 30(7):856-859. PubMed ID: 34616013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individual Oligogenic Background in p.D91A-
    Gentile G; Perrone B; Morello G; Simone IL; Andò S; Cavallaro S; Conforti FL
    Genes (Basel); 2021 Nov; 12(12):. PubMed ID: 34946792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study.
    Benatar M; Wuu J; Andersen PM; Bucelli RC; Andrews JA; Otto M; Farahany NA; Harrington EA; Chen W; Mitchell AA; Ferguson T; Chew S; Gedney L; Oakley S; Heo J; Chary S; Fanning L; Graham D; Sun P; Liu Y; Wong J; Fradette S
    Neurotherapeutics; 2022 Jul; 19(4):1248-1258. PubMed ID: 35585374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profiling tofersen as a treatment of superoxide dismutase 1 amyotrophic lateral sclerosis.
    Oliveira Santos M; de Carvalho M
    Expert Rev Neurother; 2024 Jun; 24(6):549-553. PubMed ID: 38758193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment of SOD1 ALS with tofersen: a multicentre experience in 17 patients.
    Sabatelli M; Cerri F; Zuccarino R; Patanella AK; Bernardo D; Bisogni G; Tanel R; Sansone V; Filosto M; Lattante S; Martello F; Doronzio PN; Stano S; Zanfini BA; Coccia M; Costantini EM; Lizio A; Lucioli G; Padovani A; Merlini GP; Conte A
    J Neurol; 2024 Aug; 271(8):5177-5186. PubMed ID: 38829431
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Meyer T; Schumann P; Grehl T; Weyen U; Petri S; Rödiger A; Steinbach R; Grosskreutz J; Bernsen S; Weydt P; Wolf J; Günther R; Vidovic M; Baum P; Metelmann M; Weishaupt JH; Streubel B; Kasper DC; Koc Y; Kettemann D; Norden J; Schmitt P; Walter B; Münch C; Spittel S; Maier A; Körtvélyessy P
    Amyotroph Lateral Scler Frontotemporal Degener; 2024 Sep; ():1-10. PubMed ID: 39268612
    [No Abstract]   [Full Text] [Related]  

  • 13. Compound heterozygous P67S/D91A
    De La Cruz E; Guissart C; Esselin F; Polge A; Pageot N; Taieb G; Lumbroso S; Camu W; Mouzat K
    Amyotroph Lateral Scler Frontotemporal Degener; 2022 Aug; 23(5-6):458-461. PubMed ID: 34668453
    [No Abstract]   [Full Text] [Related]  

  • 14. Tofersen: Silver Lining or Hyperbole??
    Chawla T; Goyal V
    Ann Indian Acad Neurol; 2023; 26(5):638-640. PubMed ID: 38022476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for
    Miller T; Cudkowicz M; Shaw PJ; Andersen PM; Atassi N; Bucelli RC; Genge A; Glass J; Ladha S; Ludolph AL; Maragakis NJ; McDermott CJ; Pestronk A; Ravits J; Salachas F; Trudell R; Van Damme P; Zinman L; Bennett CF; Lane R; Sandrock A; Runz H; Graham D; Houshyar H; McCampbell A; Nestorov I; Chang I; McNeill M; Fanning L; Fradette S; Ferguson TA
    N Engl J Med; 2020 Jul; 383(2):109-119. PubMed ID: 32640130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in Cerebrospinal Fluid Concentrations of Selenium Species Induced by Tofersen Administration in Subjects with Amyotrophic Lateral Sclerosis Carrying SOD1 Gene Mutations.
    Vinceti M; Urbano T; Filippini T; Bedin R; Simonini C; Sorarù G; Trojsi F; Michalke B; Mandrioli J
    Biol Trace Elem Res; 2024 Jul; ():. PubMed ID: 39017978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of tofersen treatment in patients with
    Wiesenfarth M; Dorst J; Brenner D; Elmas Z; Parlak Ö; Uzelac Z; Kandler K; Mayer K; Weiland U; Herrmann C; Schuster J; Freischmidt A; Müller K; Siebert R; Bachhuber F; Simak T; Günther K; Fröhlich E; Knehr A; Regensburger M; German A; Petri S; Grosskreutz J; Klopstock T; Reilich P; Schöberl F; Hagenacker T; Weyen U; Günther R; Vidovic M; Jentsch M; Haarmeier T; Weydt P; Valkadinov I; Hesebeck-Brinckmann J; Conrad J; Weishaupt JH; Schumann P; Körtvélyessy P; Meyer T; Ruf WP; Witzel S; Senel M; Tumani H; Ludolph AC
    EClinicalMedicine; 2024 Mar; 69():102495. PubMed ID: 38384337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breaking barriers with tofersen: Enhancing therapeutic opportunities in amyotrophic lateral sclerosis.
    Saini A; Chawla PA
    Eur J Neurol; 2024 Feb; 31(2):e16140. PubMed ID: 37975798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of
    Yilmaz R; Grehl T; Eckrich L; Marschalkowski I; Weishaupt K; Valkadinov I; Simic M; Brenner D; Andersen PM; Wolf J; Weishaupt JH
    Amyotroph Lateral Scler Frontotemporal Degener; 2023 Aug; 24(5-6):414-419. PubMed ID: 36650645
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.